AstraZeneca shareholders say they need clarity on China investigations
LONDON, Feb 5 (Reuters) - AstraZeneca (AZN.L), opens new tab investors will look past another strong set of quarterly results on Thursday to focus on the main issue overhanging shares: an investigation of a top executive by authorities in China, one of its key markets.
The group said on Oct. 31 that its China head Leon Wang, who also led its international business as an executive vice president, had been detained by the Chinese authorities. It said it did not know what the investigation was about.
Unless the company discloses fresh information about the probe and arrest at the release of fourth-quarter results, investors are likely to resume selling the stock even though the company's drug pipeline is viewed as strong, four healthcare investors and four analysts told Reuters.
"This blindsided the company," said AstraZeneca shareholder Lucy Coutts at investment firm JM Finn, noting the "void" of information about the probe.
"We don't have visibility on how or when this will be resolved," said Redburn Atlantic analyst Simon Baker. "This is the focus at the moment. It shouldn't be, but it is."
Wang's arrest was followed by other revelations, including that more than 100 former sales staff in China had been sentenced to jail time in a large and ongoing medical insurance fraud case.
In November the company reported a third investigation in China involving two current and two former senior executives, relating to the import of AstraZeneca cancer drugs from Hong Kong. It said the probe targeted only the individuals, not the company.
AstraZeneca declined to comment for this article ahead of results.
China has long been a key market for the drugmaker, the crown jewel of its international business that accounted for 13% of total sales in 2023.
The Anglo-Swedish group announced plans in 2023 to build a $450 million factory in China. It signed several licensing deals with Chinese companies that year, and bought a China-headquartered biotech company.
Chief Financial Officer Aradhana Sarin told investors at the JPMorgan Healthcare Conference last month the company anticipates some revenue impact on its China business in the fourth quarter and into 2025. Investors are hoping for more information on Thursday.
SMALL RECOVERY
AstraZeneca shares have recovered after the initial news of Wang's detention wiped around $18 billion off their value. They are up about 2% since early November.
In December, AstraZeneca replaced Wang with senior executive Iskra Reic as executive vice president for international, based in Shanghai.
Several investors said it may be tough for an executive who does not speak Mandarin and has never lived in China to navigate such a complicated market at a very sensitive time.
Barclays analysts said in a recent note they believe AstraZeneca may pay a penalty to resolve the Wang investigation. In 2014, British drugmaker GSK (GSK.L), opens new tab was fined nearly 300 million pounds ($372 million) by a Chinese court for bribery.
"Whilst there could be some commercial impact coming from lack of promotion whilst the investigation is ongoing, we view this as digestible given the momentum elsewhere in the business," Barclays said.
($1 = 0.8054 pounds)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
19 minutes ago
- Reuters
Poland cancels acquisition process for 32 Black Hawk helicopters
WARSAW, June 6 (Reuters) - Poland has cancelled the procurement procedure for the purchase of 32 more Lockheed Martin S-70i Black Hawk helicopters for the Polish Army, the Polish Armament Agency said on Friday. "Maybe it is necessary to acquire other equipment in its (helicopters') place such as drones, or tanks, or some kind of communication," agency spokesman Grzegorz Polak told Reuters. Polak added that "some correction" was needed when the geopolitical situation and state security interests required other tasks to be carried out. Poland launched negotiations for the acquisition of 32 S-70i Black Hawk helicopters, produced by Lockheed Martin's Polish arm PZL Mielec, in 2023 under the previous Law and Justice (PiS) government, opens new tab. PiS lawmaker Mariusz Blaszczak, who was defence minister in the previous government, labelled the decision a "disgrace" in a post on X, saying it would slow down the replacement of the helicopter fleet. In August 2024 Poland signed a contract with the U.S. to buy 96 AH-64E Apache attack helicopters. Under the deal with the U.S. government the helicopters would provide new combat capabilities in terms of target engagement and reconnaissance, and will replace Poland's post-Soviet Mi-24 helicopters. Polak said the Armament Agency obtained equipment in accordance with Polish army plans, which are classified. It was not the Armament Agency that set procurement priorities, he added.
Reuters
24 minutes ago
- Reuters
US declares Biden fuel economy rules exceeded legal authority
June 6 (Reuters) - The U.S. Transportation Department on Friday declared that fuel economy rules issued under then President Joe Biden exceeded the government's legal authority by including electric vehicles in setting the rules, automaker officials said Monday. The department made the declaration as it published a final "Resetting the Corporate Average Fuel Economy Program" rule. Removing EVs from the calculations for credits and the regulatory mandates will likely result in lower overall fuel economy requirements. A future separate rule from the administration of President Donald Trump will revise the specific fuel economy requirements.
Reuters
25 minutes ago
- Reuters
ECB policymakers debate risk of inflation going too low
FRANKFURT, June 6 (Reuters) - European Central Bank policymakers hailed victory over runaway inflation on Friday even as some warned that it was now at risk of going too low, rekindling memories of anaemic price growth in the pre-pandemic decade. The ECB cut interest rates on Thursday for the eighth time in the past year and signalled at least a pause in policy easing next month since inflation was now safely back at its 2% target after three years of overshooting. Part of the argument for the pause is that economic growth is better than feared, a premise underpinned by fresh data showing the euro zone economy grew by 0.6% in the first quarter, above the 0.3% estimated earlier, and retail sales were also robust. However, the strong growth figure is an anomaly, many economists say. It was driven by frontloaded exports to the United States before tariffs kicked in and data was especially distorted by Ireland, where growth is fuelled largely by activity among big foreign companies based there for tax reasons. Portuguese policymaker Mario Centeno, who has long warned about the risk of price growth going too low, said his colleagues should be alert inflation dipping too far below 2%. "The inflation rate (in the euro zone) is currently below 2% and this downward trend will worsen until the beginning of next year, when it will approach the dangerous level of 1%, or slightly above that," he said in Lisbon. "This is a scenario that should alert us," he said. Finland's Olli Rehn said there was a particular risk from the escalation of the trade war with the U.S. and the outlook was so complex, the ECB's adverse scenario could not take into account all outcomes. "For example, serious disruptions to supply chains and disruptions in financial markets have been excluded from the analysis," Rehn said in a blog post. Part of the reason inflation could go lower is that Germany, the bloc's biggest economy, will stagnate this year, marking the third year of zero or negative growth as its long-predicted recovery keeps getting pushed further and further out. While Germany's new government plans to sharply increase fiscal spending on defence and infrastructure, this will not significantly boost growth until the end of 2027, the Bundesbank said as it cut growth projections for this year and next. "Concerns about a persistent undershoot may soon resurface, especially if trade tensions escalate, weighing on demand," Oxford Economics said in a note. Others took a more benign view that was more in line with the ECB's view that inflation will rebound and hit the bank's 2% target. "The ECB's 2% inflation target has essentially been achieved," Estonian policymaker Madis Müller said. "The expected economic growth in the next couple of years is also likely to be quite moderate, which means that there is no reason to worry too much about price pressure related to the heating up of the economic environment." Latvia's Martins Kazaks said he was also comfortable with the outlook and made the case for the ECB to take a break in cutting rates, partly to preserve policy space and to await fresh data. "I don't think the market should expect the trajectory of cutting rates at every meeting to continue," he told Reuters. "There is no need and there is value in maintaining policy space."
